- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Oxidative Medicine and Cellular Longevity
Volume 2013 (2013), Article ID 306073, 10 pages
Preventive and Therapeutic Effects of MG132 by Activating Nrf2-ARE Signaling Pathway on Oxidative Stress-Induced Cardiovascular and Renal Injury
1Department of Nephrology, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun, Jilin Province 130041, China
2KCHRI at the Department of Pediatrics, University of Louisville, 570 South Preston Street, Baxter I, Suite 304F, Louisville, KY 40202, USA
3Department of Cardiology, The People’s Hospital of Jilin Province, Changchun 130021, China
Received 11 January 2013; Accepted 14 February 2013
Academic Editor: Jingbo Pi
Copyright © 2013 Wenpeng Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
So far, cardiovascular and renal diseases have brought us not only huge economic burden but also serious society problems. Since effective therapeutic strategies are still limited, to find new methods for the prevention or therapy of these diseases is important. Oxidative stress has been found to play a critical role in the initiation and progression of cardiovascular and renal diseases. In addition, activation of nuclear-factor-E2-related-factor-2- (Nrf2-) antioxidant-responsive element (ARE) signaling pathway protects cells and tissues from oxidative damage. As a proteasomal inhibitor, MG132 was reported to activate Nrf2 expression and function, which was accompanied with significant preventive and/or therapeutic effect on cardiovascular and renal diseases under most conditions; therefore, MG132 seems to be a potentially effective drug to be used in the prevention of oxidative damage. In this paper, we will summarize the information available regarding the effect of MG132 on oxidative stress-induced cardiovascular and renal damage, especially through Nrf2-ARE signaling pathway.
The World Health Organization reports that chronic diseases as the leading cause of mortality in the world cause approximately 17 million people to die prematurely each year and keep steadily growing [1, 2]. What is more, this largely invisible epidemic is the worst in low- and middle-income countries, which could forego billions of dollars in national income as a result of these diseases. For example, the estimated losses in China from 2005 to 2015 are 558 billion dollars . Cardiovascular diseases (CVD), a group of common chronic diseases, are the largest causes of morbidity and mortality worldwide. Chronic kidney disease (CKDs), also known as a microvascular disease, is an increasing public health concern too. CKD not only increases the risk of CVD and disease expenditure but also has a major impact on patients, health services, and society burden [3–5]. Thus, it is a priority to find effective drugs to treat CVD and CKD.
Epidemiological studies have shown several risk factors for patients with CVD and CKD, such as heredity [6, 7], diabetes [8, 9], anemia , and hyperlipidemia [11, 12], but nontraditional risk factors such as oxidative stress may also contribute to these diseases [13, 14]. Our understanding of how oxidative stress contributes to cardiovascular and renal diseases has undergone considerable evolution over the past two decades. In recent years, reactive oxygen species (ROS) have come to be recognized as taking part not only in normal intracellular signaling for survival, but also in contributing to cytotoxicity . Therefore, antioxidant therapy seems a preventive or therapeutic solution for the oxidative damage. Reportedly antioxidants such as vitamin E have been used in the treatment of human cardiovascular and renal disease; however, despite that there is one study supporting the therapeutic effect of vitamin E on these diseases , most of the clinical studies have failed to materially impact the course of the diseases [17, 18]. The possible reasons might include inefficiency of monoantioxidant used such as vitamin E only. Therefore, supplemental or upregulating endogenous multiple antioxidant levels may be a more efficient approach than mono-antioxidant therapy.
There are highly regulated cellular defense systems, including the redox-sensitive nuclear-factor-E2-related-factor-2- (Nrf2-) antioxidant-responsive element (ARE) pathway. Nrf2 is a transcription factor to regulate the expression of a battery of antioxidant genes and other cytoprotective phase II detoxifying enzymes through binding ARE [19, 20]. Therefore, Nrf2-ARE pathway promises to be a valuable therapeutic target for the prevention of oxidative stress and damage. Accumulating investigation has demonstrated that proteasome inhibitor MG132 could protect cells and tissues against oxidative damage because it could activate the Nrf2-ARE signaling pathway, leading to an upregulation of detoxifying and antioxidant genes [21–24]. In this paper, we thus focus on the antioxidant effect of MG132 on oxidative stress-induced cardiovascular and renal diseases.
2. Oxidative Stress and Nrf2-ARE Signaling Pathway
2.1. Oxidative Stress
ROS, a necessary evil of aerobic life, are routinely produced as a byproduct of aerobic metabolism, oxidative phosphorylation, environmental stressors, disease, or even natural aging process . ROS generation is an important signaling mechanism in cells . Our body is under constant oxidative attack from ROS so that a complex antioxidant system that generally defends this attack in balance has been evolved . Oxidative stress is defined by the imbalance between the production of ROS and the endogenous antioxidant mechanisms that counteract the effects of ROS or repair the resulting damages . Under physiological conditions, several tightly controlled oxidative pathways contribute towards ROS productions, while several endogenous antioxidant enzymatic mechanisms account for ROS depletion . Either caused by reduced detoxification or increased generation, ROS can lead to widespread and indiscriminate cellular damage. As the central cause of oxidative stress, ROS at homeostatic levels have diverse actions on cell function. For instance, ROS can activate protein kinases (such as mitogen-activated protein kinases (MAPK))  and upregulate redox-sensitive factors (such as NF κB and AP-1) [30, 31]. On the other hand, it can be detrimental to cellular homeostasis by leading to opening ion channels  and major cellular macromolecules damage, including lipid peroxidation , DNA oxidation , and protein modification . These damages, if left unrepaired, can lead to mutations that cause diseases.
2.2. Mechanism of the Nrf2-ARE Signaling Pathway in Oxidative Stress-Associated Injury
There is an upsurge of interest in Nrf2-ARE system because it plays a key role in the cell’s response to oxidative stress [36–38]. Nrf2, a cap-n-collar family of nuclear basic leucine zipper transcription factors, is the central of this system and regulates cellular defenses against ROS. Nrf2-ARE signaling pathway is regulated by complex and poorly understood mechanisms. Kelch-like ECH-associated protein 1 (Keap1), known as an actin cytoskeleton-associated protein, binds very tightly to Nrf2 and anchors this transcription factor in the cytoplasm . Keap1 also serves as a substrate adaptor for Cullin-3 (Cul3) that binds to ring-box 1 to form the E3 ubiquitin-ligase complex. The latter ultimately leads to ubiquitination and proteasomal degradation of Nrf2; thereby the ability of Nrf2 to induce phase II detoxification enzyme genes is repressed, as shown in Figure 1 [40–43].
When exposed to various stimuli such as oxidative stress, certain antioxidants, and chemopreventive agents, the Nrf2/Keap1 complex will be disrupted by modifying two (Cys273 and Cys288) of the 25 cysteine residues of Keap1 , allowing the cytoplasmic-to-nuclear translocation of Nrf2. In the nucleus, Nrf2 increases gene expression of phase II detoxifying and/or antioxidant enzymes such as glutathione S-transferase (GST), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), NAD (P) H:quinine oxidoreductase 1 (NQO1), and heme oxygenase 1 (HO-1) [45, 46]. As shown in Figure 1(b), the transcriptional activation of these antioxidant enzymes is thought to be mediated by ARE or electrophile response element, which is found at the 5-flanking region of the phase II detoxification enzyme genes .
Modification of the Nrf2/Keap1 complex and Nrf2 nuclear translocation is important to Nrf2-ARE-pathway-dependent gene expression, and several signaling pathways are associated with these processes. For example, one component of these pathways is MAPKs. Both extracellular signal-regulated kinase (ERK) and p38MAPK have been found to induce Nrf2 translocation and HO-1 expression through diallyl sulfide in HepG2 cells . In addition, protein kinase C (PKC) is also associated with Nrf2-dependent antioxidant enzyme expression. Huang et al. reported that PKC promotes Nrf2 phosphorylation at Ser-40, which yields the dissociation of Nrf2 from Keap1 in HepG2 cells. Data revealed that PKC-induced Nrf2 phosphorylation is critical to ARE-dependent antioxidant enzyme expression [49, 50]. Taken together, regulation of the upstream kinases involved, such as phosphatidylinositol 3-kinase (PI3 K), ERK, and PKC, provides a valuable tool for the investigation of Nrf2/Keap1 complex-controlled gene transcription .
3. Effects of Ubiquitin-Proteasome System (UPS) and MG132 on Nrf2-ARE Signaling Pathway
Proteins in eukaryotic cells are continually being synthesized and degraded. Two proteolytic systems, the lysosomal systems and UPS, are mainly responsible for this homeostasis. The lysosomal system is the principal mechanism for degrading proteins with long half-life and is the only system in cells for degrading organelles and large protein aggregates or inclusions . The UPS pathway, as a highly specific extralysosomal system, plays a pivotal role in the degradation of misfolded and damaged proteins within the eukaryotic cells. Moreover, the UPS is also essential for selective degradation of short-lived and regulatory proteins involved in a wide variety of fundamental cellular processes, including cell cycle control , apoptosis , transcriptional regulation , proliferation , cell surface receptors expression , ion channels modulation , and Nrf2 degradation .
The UPS consists of three parts: the 76-amino acid protein ubiquitin, the multisubunit complex 26S proteasome, and three enzymes, including ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin-ligase (E3) which are involved in a 3-step enzymatic cascade process [53, 60]. In an energy-dependent stepwise process catalyzed by three enzymes (E1, E2, and E3), target proteins for the proteasomal degradation are conjugated to multiple units of ubiquitin yielding a polyubiquitinated proteins. In the next step, unfolding ubiquitinated proteins are recognized, hydrolyzed, and then degraded by the 26S proteasome , which was illustrated in Figure 2(a). Proteasome, a highly conserved catalytic enzyme complex, is a large multisubunit protease and the most common form is known as 26S proteasome. It is composed of one catalytic 20S core particle (CP or 20S proteasome) and one or two 19S regulatory particles (RP or 19S proteasome) (Figure 2(b)). The 26S proteasome is a 2.5 MD protein complex which presents in the nucleus and cytoplasm of all eukaryotic cells [62, 63]. Known as 20S proteasome, the large core unit with a molecular mass of approximately 700 kDa is made up of two outer α rings and two inner β rings, which consists of 7 structurally similar α and β subunits, respectively . The 20S proteasome contains proteolytic active sites that are sequestered within an interior space and performs several peptidolytic functions to maintain cellular homeostasis . On the other hand, the 19S proteasome is able to recognize polyubiquitylated target proteins and take part in their deubiquitylating, unfolding, and translocation into the interior space of the 20S proteasome for destruction .
3.2. Proteasome Inhibitor MG132 and Nrf2-ARE Signaling Pathway
MG132 (Z-Leu-Leu-Leu-CHO), a peptide aldehyde proteasome inhibitor, was constructed by Roca et al. in 1994 and has been widely used in proteasome biology, allowing for the identification of new therapeutic targets and the development of novel therapeutic strategies. MG132 is a substrate analogue and potent transition-state inhibitor and mainly exhibits the chymotrypsin-like activity of the proteasome [65, 66]. When cells are exposed to this cell-permeable, potent, highly specific, and reversible proteasome inhibitor, MG132 will reduce degradation of ubiquitin-conjugated Nrf2 by inhibiting activity of the β subunits of the core particle of 26S proteasome without affecting its ATPase or isopeptidase activities. Subsequently, undegraded Nrf2 will be released from the Nrf2/Keap1 complex and translocate into the nucleus. Then Nrf2 binds to ARE and upregulates transcription of antioxidant genes (Figure 2(b)).
The stabilization of Nrf2 by proteasome inhibition and subsequent transcriptional activation of its downstream genes have been shown in different cell types in earlier studies [24, 42, 67–69]. Recently, several studies have demonstrated that MG132 has the capacity of activating Nrf2-ARE signaling pathway in a variety of disease conditions [22, 70, 71]. This antioxidant response is known to be dose dependent. Low-dose MG132 exposure improves cellular fitness accompanied by the up-regulation of heat-shock proteins, GST, and Nrf2 [22, 68, 72] while high-dose MG132 yields an opposing effect that leads to apoptosis and even severe oxidative stress [73, 74]. Although the precise mechanism by which MG132 exerts antioxidant effects has not been fully understood, one well-accepted hypothesis is that the antioxidative effect of MG132 is related to the prevention of Nrf2 degradation through its suppression of UPS and subsequent translocation of Nrf2 from cytoplasm into the nucleus . In Huang et al.’s study, the phosphorylation of Nrf2 at serine 40 appears to be a critical event in the release of Nrf2 from Keap1 and the translocation of Nrf2 from cytosol into the nucleus . However, whether MG132 can provoke Nrf2 phosphorylation remains unknown; therefore, further investigations are needed to make this mechanism clear.
Despite that MG132 inhibition of proteasome results in an elevation of Nrf2 expression, the compensative induction of proteasome activity was also noticed. For instance, elevated proteasome subunit synthesis upon proteasome inhibition by MG132 is well conserved in human squamous cells [75, 76]. Interestingly, Nrf2, as a degradation target of proteasome, was also thought to mediate the proteasome recovery by increasing the 20S proteasome and the Pa28αβ (11S) proteasome regulator protein levels through a transcriptional feedback loop . However, other studies demonstrated that the compensatory increase in proteasome subunit gene expression was Nrf1 dependent, instead of Nrf2 [75, 76]. Therefore, the exact mechanisms by which proteasomal activity is compensatively increased remain systemic studies.
4. Effect of MG132 on Oxidative Stress-Induced Cardiovascular and Renal Injury: Nrf2-Dependent Pathway
4.1. Preventive Effect of MG132
4.1.1. Cardiovascular Injury
With regard to CVD, many of the pathogenic components of the disease are associated with oxidative stress, such as inflammation, LDL oxidation, and endothelial dysfunction. Overproduction and accumulation of ROS severely damage DNA, proteins, and lipids, resulting in further tissue damage and organ dysfunction. Compelling evidence supports the idea that supraphysiological levels of ROS (or called oxidative stress) play an important role in the pathophysiology of various CVDs, including endothelial dysfunction [78, 79], atherosclerosis [80, 81], and ischemia-reperfusion injury .
Our previous study indicated that high glucose could lead to ROS generation in both primary neonatal and adult cardiomyocytes from wild-type mouse heart. Whereas, in Nrf2 knockout cells from Nrf2 knockout mice, ROS were significantly higher under basal conditions and high glucose markedly further increased ROS production in concentration- and time-dependent manners . Nrf2 was shown to mediate the basal expression and induction of ARE-controlled NQO1 and HO-1, at both mRNA and protein levels in cardiomyocytes . Persuasive evidence has suggested that activation of antioxidant genes through Nrf2-ARE-dependent mechanism might yield protection against oxidative stress-associated injury in CVD [19, 84]. This antioxidant effect of proteasome inhibitor MG132 was confirmed by a Germany group . Exposure to 0.5 μM MG132 for 48 h proved to be nontoxic and protected neonatal rat cardiac myocytes against H2O2-mediated oxidative stress . Another study from China investigated the effects of long-term MG132 treatment on cardiac hypertrophy in vivo. This study showed that treatment with MG132 (0.1 mg/kg/day) for 8 weeks attenuated pressure-overload-induced cardiac hypertrophy and improved cardiac function in abdominal aortic banding rats . Recently a study from our group showed that therapeutic effect of MG132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities . Mechanistically MG132 may upregulate Nrf2-mediated anti-oxidative function and downregulate NF-κB-mediated inflammation.
In a similar study, we treated STZ-induced diabetic mice with sulforaphane at 0.5 mg/kg daily in five days of each week for 3 months. Sulforaphane treatment completely prevented diabetes-induced aortic pathogenic changes by attenuating oxidative stress, inflammation, and fibrosis in the aorta . The aortic protection by sulforaphane treatment from diabetes was also accompanied with a significant up-regulation of Nrf2 expression and function (reflected by its downstream genes: HO-1, NQO1, and SOD1 expression) . MG132 was also used in several vascular diseases. For instance, nontoxic inhibition of the proteasome using MG132 was found to protect against oxidative stress-induced endothelial dysfunction through increasing depressed SOD1 expression . This finding is in line with a previous report that MG132 could liberate Nrf2 from Keap1 and translocate to nucleus to bind DNA with up-regulation of its downstream antioxidant genes . Hemin is released from hemoglobin after central neuronal system hemorrhage and may cause ROS accumulation which contributes to cell loss in surrounding tissue. Pretreatment with 1 μM MG132 for 2 h prevented approximately half of heme-mediated oxidative injury by up-regulation of Nrf2 and HO-1 .
4.1.2. Renal Injury
Similar to CVD, oxidative stress is also the major player in the process of many kidney diseases, including acute kidney injury (AKI) [89, 90], ischemia reperfusion-induced renal injury , primary glomerulonephritis [92–96], diabetic nephropathy [97–101], lupus nephritis [102–104], and antineutrophil cytoplasmic antibodies-associated vasculitis [105, 106].
Previous work has indicated that impaired renal function in hypercholesterolemic pigs is improved by chronic proteasome inhibition with MLN-273 . In a recent study, enhanced renal proteasome activity was found during lipopolysaccharide-induced AKI in human kidney cells. Suppression of proteasome activity using 10 μM MG132 for 18 h can attenuate lipopolysaccharide-induced AKI . In another AKI model, cisplatin-induced nephrotoxicity was markedly ameliorated by MG132 treatment both in vivo and in vitro .
Antifibrotic effect of MG132 at low doses has been observed in rat renal fibroblasts and mesangial cells [110, 111]. As we know, oxidative stress plays an important role in pathogenesis of diabetic nephropathy. Zheng et al. provided experimental evidence indicating that Nrf2-ARE signaling pathway activation by sulforaphane or cinnamic aldehyde can be used therapeutically to relieve renal damage induced by type 1 diabetes. This idea was confirmed by our recent study . We treated type 1 diabetic mice with sulforaphane at 0.5 mg/kg daily for five days for each for 3 months. At the end of 3-month treatment with sulforaphane one set of mice was sacrificed to perform the experimental measurements (3-month time point). The second set of mice was aged for 3 additional months without further sulforaphane treatment (6 month time point). Our results revealed that sulforaphane significantly prevented diabetes-induced renal inflammation, oxidative damage, and fibrosis by activation of Nrf2-ARE signaling pathway in the kidney at 3-month time point, but not at 6-month time point, suggesting the requirement of continual use of sulforaphane for its sustained effect . In another STZ-induced diabetes rat model, MG132 was administered at a dose of 10 μg/kg/day via intraperitoneal injection once daily for 3 months. After MG132 treatment, renal Nrf2 and its downstream antioxidants (SOD1, CAT, and GPx) were upregulated and diabetic renal damage was also improved .
4.2. Therapeutic Effect of MG132
4.2.1. Cardiovascular Injury
A recent study from our group suggested that therapeutic effect of MG132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities . Diabetic mice showed significant cardiac dysfunction, heart structural derangement, and remodeling (fibrosis and hypertrophy), as well as increased systemic and cardiac oxidative damage and inflammation. All of these pathogenic changes were reversed by MG132 treatment. In addition, MG132 treatment significantly increased cardiac expression of Nrf2 and its downstream antioxidant genes and also significantly decreased the expression of Iκ-B and the nuclear accumulation and DNA binding activity of NF-κB in the heart. Therefore, the possible mechanisms might include both up-regulating Nrf2-mediated anti-oxidative function and downregulating NF-κB-mediated inflammation induced by MG132.
4.2.2. Renal Injury
The therapeutic effect of MG132 on diabetic nephropathy was also reported by our group . Three-month old transgenic type 1 diabetic (OVE26) mice displayed renal dysfunction with albuminuria and then were treated with MG132 (10 μg/kg/day). After 3-month treatment with MG132, diabetes-induced renal oxidative damage, inflammation, fibrosis, and eventual dysfunction were significantly attenuated accompanied with a significant decrease in 20S proteasome activity decrease and activation of Nrf2-ARE signaling pathway. In vitro study using human renal tubular HK11 cells confirmed the role of Nrf2 in the prevention of diabetes-induced renal damage. HK11 cells were treated with high glucose (27.5 mM) for 48 h. During that time, MG132 (2 μM) and palmitate (300 μM) were added in the last 9 h and 6 h, respectively. Immunofluorescent staining for Nrf2 showed that Nrf2 expression and nuclear accumulation were decreased in high glucose plus palmitate group but increased in MG132 treatment group. MG132 treatment also significantly prevented the increase of connective tissue growth factor overexpression in the cells treated with high glucose plus palmitate. What’s more, silencing the Nrf2 gene with its specific siRNA abolished MG132 decrease of high glucose and palmitate-induced connective tissue growth factor overexpression. These results suggested that MG132 upregulates Nrf2 function via inhibition of diabetes-increased proteasomal activity, leading to the therapeutic effect on diabetic nephropathy.
4.3. Dose-Dependent Effects of MG132 on Cardiovascular and Renal Injury
It should be mentioned that whether cells have beneficial response to MG132 also depend on several factors, including the type of cells, the dose of MG132, and the exposure time. Contrast to the studies discussed above, several studies in cardiac myocytes showed an opposite conclusion. Exposure of myocytes to high doses of MG132 (10 μM) in short term enhanced the cellular damage [114, 115]. Available evidence suggests that toxic inhibition of proteasome function induces programmed cell death in proliferating endothelial cells . Similarity, proteasome inhibitor MG132 has been shown to affect cell growth and death through formation of ROS and depletion of GSH in As4.1 juxtaglomerular cells [117–119]. In order to explain this interesting phenomenon, Meiners et al. have systemically analyzed dose-dependent effects of proteasome inhibition with MG132 using human umbilical cord vein cells . They found that nontoxic doses of MG132 (70 nM) induced a defined, dose-dependent transcriptional response by up-regulating anti-oxidative enzymes (e.g., SOD1, GPx) that were accompanied by protection against H2O2-induced oxidative stress, whereas high doses of MG132 (200 nM) induced apoptosis in endothelial cells . In general, nontoxic proteasome inhibition might offer a new therapeutic approach for the treatment of oxidative stress-associated cardiovascular and renal diseases.
5. Other Mechanisms by Which MG132 Protects Cells against Oxidative Damage
Although MG132 protects cardiovascular and renal damage from oxidative stress predominantly via Nrf2-ARE signaling pathway, other possible mechanisms should not be ignored. Among these mechanisms, the relatively well-studied one is IκB-NF-κB pathway. Recent studies suggested that hyperglycemia enhances 26S proteasome activity through peroxynitrite/superoxide-mediated PA700-dependent proteasomal activation, which elevates NF-κB-mediated renal and aortic inflammatory response in early diabetes. Importantly, these alterations were abolished by MG132 administration . Another in vivo study demonstrated that MG132 attenuated oxidative stress-induced damage by suppressing NF-κB in coronary arterioles in type 2 diabetic mice, because increased NAD(P)H oxidase and NF-κB activity in diabetes was attenuated by MG132 administration . Similar situation was also found in H2O2-treated microvascular endothelial cells in vitro  and heart of rats with pressure overload in vivo . Besides I κB-NF-κB pathway, MG132 can play a key role in cellular defense system by suppressing MAPK signaling pathway [125, 126] and blocking the degradation of vascular protective molecules .
Accumulating observation has illustrated that a great range of cardiovascular and renal diseases have been associated with oxidative stress. Given that Nrf2-ARE signaling pathway plays critical roles in preventing oxidative stress-associated injury, Nrf2 activators are supposed to be used clinically as a new strategy. In a phase 2, double-blind, randomized, placebo-controlled clinic trial, Dinkova-Kostova et al. used bardoxolone methyl, which has the ability to activate Nrf2 , to treat 227 patients with CKD for 52 weeks . Results suggested that patients receiving bardoxolone methyl had significant increases in estimated glomerular filter rate compared with those given placebo, accompanied by only mild adverse effects, such as muscle spasms, hypomagnesemia, and gastrointestinal effects. Similar outcomes were obtained in a subgroup study for diabetic nephropathy . With the recent US Food and Drug Administration approval of bortezomib (Velcade1) for the treatment of relapsed multiple myeloma, the proteasome inhibition has been established as a powerful and promising therapeutic strategy for oxidative stress damage [130, 131]. Although, to our knowledge, no evidence has been proved that MG132 can be used in patients with oxidative stress-induced cardiovascular and kidney diseases, it is increasingly apparent that MG132 has the antioxidant effect by up-regulation of Nrf2-ARE signaling pathway both in vitro and in vivo. Thus, MG132 may become another candidate for clinical application for the patients with cardiovascular and renal diseases. However, what is the dose window of MG132 in treatment of oxidative damage in human disease? What is the mechanism of MG132 to promote Nrf2 to release from Keap1? All these questions remain unanswered yet. Therefore, further research focusing on the effect of MG132 on Nrf2-ARE signaling pathway and the underlying mechanisms is urgently needed.
The cited works from the laboratories of the authors were supported in part by the Basic Research Award from American Diabetes Association (1-11-BA-17 to L. Cai) and the National Natural Science Foundation of China (81200525 to W. Cui). No potential conflict of interests relevant to this paper was reported.
- “Stop the global epidemic of chronic disease—new report, preventing chronic diseases: a vital investment estimates hundreds of billions of dollars at stake,” Indian Journal of Medical Sciences, vol. 59, no. 10, pp. 463–465, 2005.
- A. Morabia and T. Abel, “The WHO report “Preventing chronic diseases: a vital investment” and us,” Sozial- und Praventivmedizin, vol. 51, no. 2, p. 74, 2006.
- A. R. Nissenson, B. J. G. Pereira, A. J. Collins, and E. P. Steinberg, “Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization,” American Journal of Kidney Diseases, vol. 37, no. 6, pp. 1177–1183, 2001.
- M. R. Weir, “Recognizing the link between chronic kidney disease and cardiovascular disease,” American Journal of Managed Care, vol. 17, supplement 15, pp. S396–S402, 2011.
- E. L. Schiffrin, M. L. Lipman, and J. F. E. Mann, “Chronic kidney disease: effects on the cardiovascular system,” Circulation, vol. 116, no. 1, pp. 85–97, 2007.
- W. Cui, B. Du, W. Zhou, et al., “Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: a systematic review and meta-analysis,” Molecular Biology Reports, vol. 39, no. 8, pp. 8551–8558, 2012.
- W. P. Cui, B. Du, Y. Jia, et al., “Is C677T polymorphism in methylenetetrahydrofolate reductase gene a risk factor for diabetic nephropathy or diabetes mellitus in a Chinese population?” Archives of Medical Research, vol. 43, no. 1, pp. 42–50, 2012.
- N. J. Wareham and R. Pfister, “Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk,” Nature Reviews Cardiology, vol. 7, no. 7, pp. 367–368, 2010.
- J. P. Lea, W. M. McClellan, C. Melcher, E. Gladstone, and T. Hostetter, “CKD risk factors reported by primary care physicians: do guidelines make a difference?” American Journal of Kidney Diseases, vol. 47, no. 1, pp. 72–77, 2006.
- K. Tsuruya and H. Hirakata, “Anemia as a risk factor for CKD and CVD,” Nippon Rinsho, vol. 66, no. 9, pp. 1786–1793, 2008.
- M. Chu, A. Y. Wang, I. H. Chan, S. H. Chui, and C. W. Lam, “Serum small-dense LDL abnormalities in chronic renal disease patients,” British Journal of Biomedical Science, vol. 69, no. 3, pp. 99–102, 2012.
- S. Ansar, J. Koska, and P. D. Reaven, “Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins,” Cardiovascular Diabetology, vol. 10, article 61, 2011.
- L. F. Ramos, A. Shintani, T. A. Ikizler, and J. Himmelfarb, “Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 593–599, 2008.
- J. V. Higdon and B. Frei, “Obesity and oxidative stress: a direct link to CVD?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 3, pp. 365–367, 2003.
- G. J. Burton and E. Jauniaux, “Oxidative stress,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 25, no. 3, pp. 287–299, 2011.
- M. Boaz, S. Smetana, T. Weinstein et al., “Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial,” The Lancet, vol. 356, no. 9237, pp. 1213–1218, 2000.
- M. H. W. A. Wijnen, H. L. Vader, A. W. L. Van Den Wall Bake, and R. M. H. Roumen, “Can renal dysfunction after infra-renal aortic aneurysm repair be modified by multi-antioxidant supplementation?” Journal of Cardiovascular Surgery, vol. 43, no. 4, pp. 483–488, 2002.
- J. F. E. Mann, E. M. Lonn, Q. Yi et al., “Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE Study,” Kidney International, vol. 65, no. 4, pp. 1375–1380, 2004.
- V. R. Muthusamy, S. Kannan, K. Sadhaasivam, et al., “Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium,” Free Radical Biology & Medicine, vol. 52, no. 2, pp. 366–376, 2012.
- V. Krajka-Kuzniak, J. Paluszczak, L. Celewicz, J. Barciszewski, and W. Baer-Dubowska, “Phloretamide, an apple phenolic compound, activates the Nrf2/ARE pathway in human hepatocytes,” Food and Chemical Toxicology, vol. 51, pp. 202–209, 2013.
- W. Duan, Y. Guo, H. Jiang, X. Yu, and C. Li, “MG132 enhances neurite outgrowth in neurons overexpressing mutant TAR DNA-binding protein-43 via increase of HO-1,” Brain Research, vol. 1397, pp. 1–9, 2011.
- Z. F. Luo, W. Qi, B. Feng et al., “Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome,” Life Sciences, vol. 88, no. 11-12, pp. 512–520, 2011.
- H. Dreger, K. Westphal, A. Weller et al., “Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection,” Cardiovascular Research, vol. 83, no. 2, pp. 354–361, 2009.
- S. K. Sahni, E. Rydkina, and A. Sahni, “The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells,” Thrombosis Research, vol. 122, no. 6, pp. 820–825, 2008.
- C. T. Aiken, R. M. Kaake, X. Wang, and L. Huang, “Oxidative stress-mediated regulation of proteasome complexes,” Molecular and Cellular Proteomics, vol. 10, no. 5, Article ID R110.006924, 2011.
- B. D'Autréaux and M. B. Toledano, “ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813–824, 2007.
- W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002.
- V. V. Lyakhovich, V. A. Vavilin, N. K. Zenkov, and E. B. Menshchikova, “Active defense under oxidative stress. The antioxidant responsive element,” Biochemistry, vol. 71, no. 9, pp. 962–974, 2006.
- C. Mo, Y. Dai, N. Kang, L. Cui, and W. He, “Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways,” The Journal of Biological Chemistry, vol. 287, no. 23, pp. 19242–19254, 2012.
- V. Williams, S. Brichler, E. Khan, et al., “Large hepatitis delta antigen activates STAT-3 and NF-kappaB via oxidative stress,” Journal of Viral Hepatitis, vol. 19, no. 10, pp. 744–753, 2012.
- W. C. Chiu, C. J. Chen, T. S. Lee, Z. J. Chen, P. H. Ke, and A. N. Chiang, “Oxidative stress enhances AP-1 and NF-κB-mediated regulation of β2-Glycoprotein I gene expression in hepatoma cells,” Journal of Cellular Biochemistry, vol. 111, no. 4, pp. 988–998, 2010.
- L. C. Hool and B. Corry, “Redox control of calcium channels: from mechanisms to therapeutic opportunities,” Antioxidants and Redox Signaling, vol. 9, no. 4, pp. 409–435, 2007.
- N. J. Pillon, M. L. Croze, R. E. Vella, L. Soulere, M. Lagarde, and C. O. Soulage, “The lipid peroxidation by-product 4-hydroxy-2-nonenal (4-HNE) induces insulin resistance in skeletal muscle through both carbonyl and oxidative stress,” Endocrinology, vol. 153, no. 5, pp. 2099–2111, 2012.
- Y. Kaya, A. Cebi, N. Soylemez, H. Demir, H. H. Alp, and E. Bakan, “Correlations between oxidative DNA damage, oxidative stress and coenzyme Q10 in patients with coronary artery disease,” International Journal of Medical Sciences, vol. 9, no. 8, pp. 621–626, 2012.
- P. Piomboni, A. Stendardi, L. Gambera, et al., “Protein modification as oxidative stress marker in normal and pathological human seminal plasma,” Redox Report, vol. 17, no. 5, pp. 227–232, 2012.
- T. Nguyen, P. J. Sherratt, and C. B. Pickett, “Regulatory mechanisms controlling gene expression mediated by the antioxidant response element,” Annual Review of Pharmacology and Toxicology, vol. 43, pp. 233–260, 2003.
- J. Alam and J. L. Cook, “Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway,” Current Pharmaceutical Design, vol. 9, no. 30, pp. 2499–2511, 2003.
- A. N. T. Kong, E. Owuor, R. Yu et al., “Induction of xenobiotic enzymes by the map kinase pathway and the antioxidant or electrophile response element (ARE/EpRE),” Drug Metabolism Reviews, vol. 33, no. 3-4, pp. 255–271, 2001.
- J. D. Hayes and M. McMahon, “NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer,” Trends in Biochemical Sciences, vol. 34, no. 4, pp. 176–188, 2009.
- K. Itoh, N. Wakabayashi, Y. Katoh et al., “Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain,” Genes and Development, vol. 13, no. 1, pp. 76–86, 1999.
- K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, T. O'Connor, and M. Yamamoto, “Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles,” Genes to Cells, vol. 8, no. 4, pp. 379–391, 2003.
- D. Stewart, E. Killeen, R. Naquin, S. Alam, and J. Alam, “Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium,” The Journal of Biological Chemistry, vol. 278, no. 4, pp. 2396–2402, 2003.
- A. T. Dinkova-Kostova, W. D. Holtzclaw, R. N. Cole et al., “Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11908–11913, 2002.
- N. Wakabayashi, A. T. Dinkova-Kostova, W. D. Holtzclaw et al., “Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2040–2045, 2004.
- K. J. Min, J. H. Kim, I. Jou, and E. H. Joe, “Adenosine induces hemeoxygenase-1 expression in microglia through the activation of phosphatidylinositol 3-kinase and nuclear factor E2-related factor 2,” GLIA, vol. 56, no. 9, pp. 1028–1037, 2008.
- S. Kalayarasan, P. N. Prabhu, N. Sriram, R. Manikandan, M. Arumugam, and G. Sudhandiran, “Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats,” European Journal of Pharmacology, vol. 606, no. 1–3, pp. 162–171, 2009.
- K. Itoh, T. Chiba, S. Takahashi et al., “An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313–322, 1997.
- P. Gong, B. Hu, and A. I. Cederbaum, “Diallyl sulfide induces heme oxygenase-1 through MAPK pathway,” Archives of Biochemistry and Biophysics, vol. 432, no. 2, pp. 252–260, 2004.
- H. C. Huang, T. Nguyen, and C. B. Pickett, “Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription,” The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42769–42774, 2002.
- H. C. Huang, T. Nguyen, and C. B. Pickett, “Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12475–12480, 2000.
- G. Shen, W. S. Jeong, R. Hu, and A. N. T. Kong, “Regulation of Nrf2, NF-κB, and AP-1 signaling pathways by chemopreventive agents,” Antioxidants and Redox Signaling, vol. 7, no. 11-12, pp. 1648–1663, 2005.
- R. A. Nixon, “Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up,” American Journal of Pathology, vol. 164, no. 3, pp. 757–761, 2004.
- P. J. Vlachostergios, I. A. Voutsadakis, and C. N. Papandreou, “The ubiquitin-proteasome system in glioma cell cycle control,” Cell Division, vol. 7, article 18, 2012.
- W. Sohns, T. A. B. van Veen, and M. A. G. van der Heyden, “Regulatory roles of the ubiquitin-proteasome system in cardiomyocyte apoptosis,” Current Molecular Medicine, vol. 10, no. 1, pp. 1–13, 2010.
- K. P. Bhat and S. F. Greer, “Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation,” Biochimica et Biophysica Acta, vol. 1809, no. 2, pp. 150–155, 2011.
- F. Imai, A. Yoshizawa, N. Fujimori-Tonou, K. Kawakami, and I. Masai, “The ubiquitin proteasome system is required for cell proliferation of the lens epithelium and for differentiation of lens fiber cells in zebrafish,” Development, vol. 137, no. 19, pp. 3257–3268, 2010.
- K. Rezvani, Y. Teng, and M. De Biasi, “The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors,” Journal of Molecular Neuroscience, vol. 40, no. 1-2, pp. 177–184, 2010.
- U. Bahrudin, K. Morikawa, A. Takeuchi, et al., “Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction,” Journal of Molecular Biology, vol. 413, no. 4, pp. 857–878, 2011.
- N. F. Villeneuve, A. Lau, and D. D. Zhang, “Regulation of the Nrf2-keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases,” Antioxidants and Redox Signaling, vol. 13, no. 11, pp. 1699–1712, 2010.
- J. Adams, “The proteasome: structure, function, and role in the cell,” Cancer Treatment Reviews, vol. 29, supplement 1, pp. 3–9, 2003.
- Z. Chen, J. Hagler, V. J. Palombella et al., “Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway,” Genes and Development, vol. 9, no. 13, pp. 1586–1597, 1995.
- K. Tanaka, T. Mizushima, and Y. Saeki, “The proteasome: molecular machinery and pathophysiological roles,” Biological Chemistry, vol. 393, no. 4, pp. 217–234, 2012.
- S. Nickell, F. Beck, S. H. W. Scheres et al., “Insights into the molecular architecture of the 26S proteasome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 11943–11947, 2009.
- A. L. Goldberg, R. Stein, and J. Adams, “New insights into proteasome function: from archaebacteria to drug development,” Chemistry and Biology, vol. 2, no. 8, pp. 503–508, 1995.
- D. H. Lee and A. L. Goldberg, “Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae,” The Journal of Biological Chemistry, vol. 271, no. 44, pp. 27280–27284, 1996.
- M. Majetschak, M. B. Patel, L. T. Sorell, C. Liotta, S. Li, and S. M. Pham, “Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model,” Biochemical and Biophysical Research Communications, vol. 365, no. 4, pp. 882–888, 2008.
- N. Yamamoto, H. Sawada, Y. Izumi et al., “Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease,” The Journal of Biological Chemistry, vol. 282, no. 7, pp. 4364–4372, 2007.
- H. Usami, Y. Kusano, T. Kumagai et al., “Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors,” The Journal of Biological Chemistry, vol. 280, no. 26, pp. 25267–25276, 2005.
- T. Nguyen, P. J. Sherratt, H. C. Huang, C. S. Yang, and C. B. Pickett, “Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: degradation of Nrf2 by the 26 S proteasome,” The Journal of Biological Chemistry, vol. 278, no. 7, pp. 4536–4541, 2003.
- D. C. Kraft, C. C. Deocaris, R. Wadhwa, and S. I. S. Rattan, “Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aging human skin fibroblasts,” Annals of the New York Academy of Sciences, vol. 1067, no. 1, pp. 420–424, 2006.
- M. Lorenz, N. Wilck, S. Meiners et al., “Proteasome inhibition prevents experimentally-induced endothelial dysfunction,” Life Sciences, vol. 84, no. 25-26, pp. 929–934, 2009.
- Z. X. Du, H. Y. Zhang, X. Meng et al., “Proteasome inhibitor MG132 induces BAG3 expression through activation of heat shock factor 1,” Journal of Cellular Physiology, vol. 218, no. 3, pp. 631–637, 2009.
- A. Zanotto-Filho, E. Braganhol, A. M. Battastini, and J. C. Moreira, “Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling,” Investigational New Drugs, vol. 30, no. 6, pp. 2252–2262, 2012.
- W. H. Park and S. H. Kim, “MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion,” Oncology Reports, vol. 27, no. 4, pp. 1284–1291, 2012.
- S. Balasubramanian, S. Kanade, B. Han, and R. L. Eckert, “A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level,” The Journal of Biological Chemistry, vol. 287, no. 43, pp. 36179–36189, 2012.
- S. K. Radhakrishnan, C. S. Lee, P. Young, A. Beskow, J. Y. Chan, and R. J. Deshaies, “Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells,” Molecular Cell, vol. 38, no. 1, pp. 17–28, 2010.
- A. M. Pickering, R. A. Linder, H. Zhang, H. J. Forman, and K. J. Davies, “Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10021–10031, 2012.
- A. Fratta Pasini, A. Albiero, C. Stranieri, et al., “Serum oxidative stress-induced repression of Nrf2 and GSH depletion: a mechanism potentially involved in endothelial dysfunction of young smokers,” PLoS One, vol. 7, no. 1, Article ID e30291, 2012.
- C. Gebhard, B. E. Stahli, Y. Shi, et al., “Poly(ADP-ribose) polymerase-1 protects from oxidative stress induced endothelial dysfunction,” Biochemical and Biophysical Research Communications, vol. 414, no. 4, pp. 641–646, 2011.
- M. G. Andreassi, “Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage,” Mutation Research, vol. 543, no. 1, pp. 67–86, 2003.
- K. Gray and M. Bennett, “Role of DNA damage in atherosclerosis–bystander or participant?” Biochemical Pharmacology, vol. 82, no. 7, pp. 693–700, 2011.
- J. Neuzil, B. S. Rayner, H. C. Lowe, and P. K. Witting, “Oxidative stress in myocardial ischaemia reperfusion injury: a renewed focus on a long-standing area of heart research,” Redox Report, vol. 10, no. 4, pp. 187–197, 2005.
- X. He, H. Kan, L. Cai, and Q. Ma, “Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 1, pp. 47–58, 2009.
- X. L. Chen, G. Dodd, S. Thomas et al., “Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression,” American Journal of Physiology, vol. 290, no. 5, pp. H1862–H1870, 2006.
- B. Chen, Y. Ma, R. Meng et al., “MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals,” Acta Biochimica et Biophysica Sinica, vol. 42, no. 4, pp. 253–258, 2010.
- Y. Wang, W. Sun, B. Du, et al., “Therapeutic effect of MG132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB,” American Journal of Physiology, vol. 304, no. 4, pp. 567–578, 2013.
- X. Miao, Y. Bai, W. Su, et al., “Sulforaphane prevention of diabetes-induced aortic damage was associated with the up-regulation of Nrf2 and its down-stream antioxidants,” Nutrition & Metabolism, vol. 9, no. 1, p. 84, 2012.
- J. Chen and R. F. Regan, “Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury,” Current Neurovascular Research, vol. 2, no. 3, pp. 189–196, 2005.
- J. M. Alonso de Vega, J. Díaz, E. Serrano, and L. F. Carbonell, “Oxidative stress in critically ill patients with systemic inflammatory response syndrome,” Critical Care Medicine, vol. 30, no. 8, pp. 1782–1786, 2002.
- B. A. Molitoris and J. Marrs, “The role of cell adhesion molecules in ischemic acute renal failure,” American Journal of Medicine, vol. 106, no. 5, pp. 583–592, 1999.
- Q. Sun, Q. T. Meng, Y. Jiang, and Z. Y. Xia, “Ginsenoside Rb1 attenuates intestinal ischemia reperfusion induced renal injury by activating Nrf2/ARE pathway,” Molecules, vol. 17, no. 6, pp. 7195–7205, 2012.
- W. G. Couser and M. Nangaku, “Cellular and molecular biology of membranous nephropathy,” Journal of Nephrology, vol. 19, no. 6, pp. 699–705, 2006.
- T. J. Neale, P. P. Ojha, M. Exner et al., “Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen,” The Journal of Clinical Investigation, vol. 94, no. 4, pp. 1577–1584, 1994.
- B. Rodríguez-Iturbe, N. D. Vaziri, J. Herrera-Acosta, and R. J. Johnson, “Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all,” American Journal of Physiology, vol. 286, no. 4, pp. F606–F616, 2004.
- M. N. Budisavljevic, L. Hodge, K. Barber et al., “Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis,” American Journal of Physiology, vol. 285, no. 6, pp. F1138–F1148, 2003.
- S. V. Shah, “Oxidants and iron in chronic kidney disease,” Kidney International, Supplement, vol. 66, no. 91, pp. S50–S55, 2004.
- H. B. Lee, M. R. Yu, Y. Yang, Z. Jiang, and H. Ha, “Reactive oxygen species-regulated signaling pathways in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 8, supplement 3, pp. S241–S245, 2003.
- M. A. Lal, H. Brismar, A. C. Eklöf, and A. Aperia, “Role of oxidative stress in advanced glycation end product-induced mesangial cell activation,” Kidney International, vol. 61, no. 6, pp. 2006–2014, 2002.
- B. P. Kang, S. Frencher, V. Reddy, A. Kessler, A. Malhotra, and L. G. Meggs, “High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism,” American Journal of Physiology, vol. 284, no. 3, pp. 455–466, 2003.
- M. C. Iglesias-De La Cruz, P. Ruiz-Torres, J. Alcamí et al., “Hydrogen peroxide increases extracellular matrix mRNA through TGF-β in human mesangial cells,” Kidney International, vol. 59, no. 1, pp. 87–95, 2001.
- D. Ozcelik, M. Naziroglu, M. Tuncdemir, O. Celik, M. Ozturk, and M. F. Flores-Arce, “Zinc supplementation attenuates metallothionein and oxidative stress changes in kidney of streptozotocin-induced diabetic rats,” Biological Trace Element Research, vol. 150, no. 1–3, pp. 342–349, 2012.
- M. H. Foster, “T cells and B cells in lupus nephritis,” Seminars in Nephrology, vol. 27, no. 1, pp. 47–58, 2007.
- K. Yoh, K. Itoh, A. Enomoto et al., “Nrf2-deficient female mice develop lupus-like autoimmune nephritis,” Kidney International, vol. 60, no. 4, pp. 1343–1353, 2001.
- G. Moroni, C. Novembrino, S. Quaglini et al., “Oxidative stress and homocysteine metabolism in patients with lupus nephritis,” Lupus, vol. 19, no. 1, pp. 65–72, 2010.
- R. J. Falk and J. C. Jennette, “ANCA are pathogenicoh—oh yes they are!,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1977–1979, 2002.
- L. Harper, Y. Ren, J. Savill, D. Adu, and C. O. S. Savage, “Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages,” American Journal of Pathology, vol. 157, no. 1, pp. 211–220, 2000.
- A. R. Chade, J. Herrmann, X. Zhu, J. D. Krier, A. Lerman, and L. O. Lerman, “Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1005–1012, 2005.
- P. K. Chatterjee, M. M. Yeboah, O. Dowling, et al., “Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in mice by suppressing inflammation and proteasome activity,” PLoS One, vol. 7, no. 5, Article ID e35361, 2012.
- L. Liu, C. Yang, C. Herzog, R. Seth, and G. P. Kaushal, “Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity,” Biochemical Pharmacology, vol. 79, no. 2, pp. 137–146, 2010.
- T. Sakairi, K. Hiromura, S. Takahashi et al., “Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo,” Nephrology, vol. 16, no. 1, pp. 76–86, 2011.
- H. Wu, W. Jiang, Y. Zhang et al., “Regulation of intracellular decorin via proteasome degradation in rat mesangial cells,” Journal of Cellular Biochemistry, vol. 111, no. 4, pp. 1010–1019, 2010.
- W. Cui, Y. Bai, X. Miao, et al., “Prevention of diabetic nephropathy by sulforaphane: possible role of nrf2 upregulation and activation,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 821936, 12 pages, 2012.
- W. Cui, B. Li, Y. Bai, et al., “Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice,” American Journal of Physiology, vol. 304, no. 1, pp. 87–99, 2013.
- K. Stangl, C. Günther, T. Frank et al., “Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection,” Biochemical and Biophysical Research Communications, vol. 291, no. 3, pp. 542–549, 2002.
- H. Lüss, W. Schmitz, and J. Neumann, “A proteasome inhibitor confers cardioprotection,” Cardiovascular Research, vol. 54, no. 1, pp. 140–151, 2002.
- H. C. A. Drexler, W. Risau, and M. A. Konerding, “Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells,” FASEB Journal, vol. 14, no. 1, pp. 65–77, 2000.
- Y. H. Han, S. Z. Kim, S. H. Kim, and W. H. Park, “Treatment with p38 inhibitor intensifies the death of MG132-treated As4.1 juxtaglomerular cells via the enhancement of GSH depletion,” Drug and Chemical Toxicology, vol. 33, no. 4, pp. 367–376, 2010.
- Y. H. Han and W. H. Park, “The changes of reactive oxygen species and glutathione by MG132, a proteasome inhibitor affect As4.1 juxtaglomerular cell growth and death,” Chemico-Biological Interactions, vol. 184, no. 3, pp. 319–327, 2010.
- Y. H. Han and W. H. Park, “Proteasome inhibitor MG132 reduces growth of As4.1 juxtaglomerular cells via caspase-independent apoptosis,” Archives of Toxicology, vol. 84, no. 9, pp. 689–698, 2010.
- S. Meiners, A. Ludwig, M. Lorenz et al., “Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells,” Free Radical Biology and Medicine, vol. 40, no. 12, pp. 2232–2241, 2006.
- H. Liu, S. Yu, W. Xu, and J. Xu, “Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2131–2140, 2012.
- X. Gao, H. Zhang, A. M. Schmidt, and C. Zhang, “AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic mice,” American Journal of Physiology, vol. 295, no. 2, pp. H491–H498, 2008.
- K. Kolev, J. Skopál, L. Simon, É. Csonka, R. Machovich, and Z. Nagy, “Matrix metalloproteinase-9 expression in post-hypoxic human brain capillary endothelial cells: H2O2 as a trigger and NF-κB as a signal transducer,” Thrombosis and Haemostasis, vol. 90, no. 3, pp. 528–537, 2003.
- Y. Ma, Y. Chen, Y. Yang, et al., “Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression,” Biochemical Pharmacology, vol. 85, no. 2, pp. 223–233, 2013.
- A. B. Singh, R. S. Guleria, I. T. Nizamutdinova, K. M. Baker, and J. Pan, “High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling,” Journal of Cellular Physiology, vol. 227, no. 6, pp. 2632–2644, 2012.
- S. Wang, M. Zhang, B. Liang et al., “AMPKα2 deletion causes aberrant expression and activation of NAD(P)H Oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes,” Circulation Research, vol. 106, no. 6, pp. 1117–1128, 2010.
- J. Xu, S. Wang, M. Zhang, Q. Wang, S. Asfa, and M. H. Zou, “Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors,” PloS One, vol. 7, no. 1, Article ID e29649, 2012.
- A. T. Dinkova-Kostova, K. T. Liby, K. K. Stephenson et al., “Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 12, pp. 4584–4589, 2005.
- P. E. Pergola, P. Raskin, R. D. Toto et al., “Bardoxolone methyl and kidney function in CKD with type 2 diabetes,” The New England Journal of Medicine, vol. 365, no. 4, pp. 327–336, 2011.
- B. S. Moore, A. S. Eustáquio, and R. P. McGlinchey, “Advances in and applications of proteasome inhibitors,” Current Opinion in Chemical Biology, vol. 12, no. 4, pp. 434–440, 2008.
- D. Chauhan, T. Hideshima, and K. C. Anderson, “A novel proteasome inhibitor NPI-0052 as an anticancer therapy,” British Journal of Cancer, vol. 95, no. 8, pp. 961–965, 2006.